Compare HAIN & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HAIN | GANX |
|---|---|---|
| Founded | 1993 | 2017 |
| Country | United States | United States |
| Employees | 2600 | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.2M | 78.2M |
| IPO Year | 1996 | 2021 |
| Metric | HAIN | GANX |
|---|---|---|
| Price | $0.74 | $1.59 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | $2.23 | ★ $7.50 |
| AVG Volume (30 Days) | ★ 1.1M | 485.7K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.46 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,457,769,000.00 | $55,180.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.55 | $1.41 |
| 52 Week High | $2.08 | $4.34 |
| Indicator | HAIN | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 47.33 | 32.36 |
| Support Level | $0.58 | N/A |
| Resistance Level | $0.82 | $2.09 |
| Average True Range (ATR) | 0.08 | 0.10 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 59.48 | 14.29 |
The Hain Celestial Group Inc is a health and wellness company. It makes natural and organic food and personal-care products. The company offers products across various categories such as snacks, baby & kids food, beverages, meal preparation, and personal care through brands like Garden Veggie Snacks, Terra chips, Garden of Eatin snacks, Hartley's Jelly, and Celestial Seasonings teas, among others. It operates under two reportable segments: North America and International. The majority of its revenue is derived from the North America segment, which represents the sale of its products in the United States and Canada. The International segment includes the sale of its products in the United Kingdom and the Western European region.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.